Stans, Switzerland, June 28, 2016

THERAMetrics holding AG (the “Company”) announces today that it expects its business combination with Relief Therapeutics SA (Relief) to be completed by mid-July 2016.

The Company, the shareholders of Relief Therapeutics SA (the “Relief Shareholders”) and GEM Global Yield Fund LLC S.C.S (“GEM Fund”) entered into an amendment to the original agreement, dated 19 December 2015, allowing more time for the Relief Shareholders to meet a condition precedent to the closing. At the same time, GEM Fund has committed to provide THERAMetrics with approx. CHF 2 million in cash by August 25, 2016. This commitment replaces GEM Fund’s previous commitment to provide such funds directly to Relief Therapeutics SA

About Therametrics holding AG

THERAMetrics holding AG is a drug development company with a portfolio of drug candidates focussing on clinical stage projects of natural human origins. The company is listed on the SIX Swiss Exchange under the symbol TMX and is headquartered in Stans, Switzerland.

About Relief Therapeutics SA

Relief Therapeutics SA is a clinical stage biotechnology company incorporated in May 2013 by Gaël Hédou, Michel Dreano and Yves Sagot, former Merck Serono employees. The mission of the company is to develop innovative treatments to address high unmet medical needs. In particular, the most advanced program aims at providing a cure for the debilitating affections that are associated with degeneration of the peripheral nervous system (neuropathy).

About Global Emerging Market (GEM)

Global Emerging Markets was founded in 1991. GEM is a USD 3.4 billion investment group having completed 365 transactions in 65 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. GEM’s funds include: CITIC-GEM Fund, Kinderhook, GEM Global Yield Fund, GEM India and VC Bank/GEM Mena Fund*.
(*GEM exited both its LP and GP stakes in Q1 2010.)